Earnings Roundup: Johnson & Johnson Results Are Better Than They Appear
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 17, 5:30PM CDT
Investors focusing on Johnson and Johnson 's 3.5% top-line revenue growth in the first quarter are likely walking away unimpressed. However, tepid results in the company's medical device and consumer goods business mask much stronger growth in...
Final Glance: Biotechnology companies
AP - Thu Apr 17, 5:01PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Has A Streamlined FDA Raised The Value Of Drug Stocks?
at Investor's Business Daily - Thu Apr 17, 4:33PM CDT
Last month, three Democrats from the U.S. Congress sent a now-famous letter to Gilead Sciences (GILD) questioning the $84,000 price of its new blockbuster hepatitis C medicine, Sovaldi. Among the reasons raising suspicions that the price didn't need...
Earnings Primer: What's on Deck for Celgene, AbbVie, and Gilead
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 17, 1:30PM CDT
Biotech stocks have taken a punishing nose-dive over the past month as investors step aside following significant gains. However, the current share slide is likely more a result of emotion than any long-term changes at drug developer heavyweights ...
If This Biotech Drops Much Further I'm Going to Buy It!
Sean Williams, The Motley Fool - Motley Fool - Thu Apr 17, 12:05PM CDT
We've seen a little bit of a relief rally over the past couple of days in the overall market with the start of earnings season giving investors hope that the U.S. economy and corporations can keep motoring higher. On the all, though, it's been a...
Early Glance: Biotechnology companies
AP - Thu Apr 17, 10:31AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
UnitedHealth's 1Q profit tumbles 8 percent
By TOM MURPHY - AP - Thu Apr 17, 10:18AM CDT
UnitedHealth Group's first-quarter net income slid 8 percent as funding cuts to a key product and costs imposed by the health care overhaul dented the health insurer's performance.
Managers See Buys in Choppy Markets, Including Gilead, LinkedIn
at The Street - Thu Apr 17, 8:41AM CDT
Fund managers point to rich opportunity in choppy markets, even for those bearish on market direction.
Will Merck & Co. Inc Unseat Biotech's Hottest Drug?
Dan Carroll, The Motley Fool - Motley Fool - Thu Apr 17, 8:30AM CDT
No drug has hit the market running like Gilead Sciences ' freshly approved oral hepatitis C drug Sovaldi. In a market that analysts estimate could be worth up to $20 billion, Sovaldi's made a huge impact in gaining regulatory approval first in the...
Biotech Stock Mailbag: NeoStem, Gilead and the Importance of Big-Cap Biotech Earnings
at The Street - Thu Apr 17, 8:18AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Young Scientists From Around the State Will Compete for Top Honors at the 63rd California State Science Fair
PR Newswire - Wed Apr 16, 5:31PM CDT
Over 1,000 of the state's top middle and high school students will convene for the final round of competition in the 63rd annual California State Science Fair, April 28-29, 2014 at the California Science Center in Exposition Park. Winners will take home a combined total of more than $50,000 in cash prizes. The Fair's presenting sponsor is Northrop Grumman Corporation with additional support from Chevron Corporation, Southern California Gas Company, THE MUSES of the California Science Center Foundation, The Ralph M. Parsons Foundation and Gilead Sciences, Inc.
Gilead Sciences, Inc. Feeling Sovaldi Pressure From All Sides
Cory Renauer, The Motley Fool - Motley Fool - Wed Apr 16, 5:30PM CDT
One of the sparks that ignited the recent biotech sell-off was the backlash over the cost of Gilead Sciences ' highly effective hepatitis C therapy. While much of the industry needed a reality check, it looks like the market has overreacted to...
3 Stocks to Get on Your Watchlist
Sean Williams, The Motley Fool - Motley Fool - Wed Apr 16, 4:03PM CDT
I follow quite a lot of companies, so the usefulness of a watchlist for me cannot be overstated. Without my watchlist, I'd be unable to keep up with my favorite sectors and see what's really moving the market. Even worse, I'd be lost when the time...
Watch for Gilead Sciences to Potentially Pullback After Gaining 1.63% Yesterday
Comtex SmarTrend(R) - Wed Apr 16, 3:48PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $68.34 to a high of $69.89. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $69.14 on volume of 17.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Gilead Sciences Rises 1.63% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Apr 16, 3:48PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $68.34 to a high of $69.89. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $69.14 on volume of 17.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Johnson and Johnson Earnings Surprises With Blockbuster Potential
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Wed Apr 16, 1:52PM CDT
Editor's Note: In the video below, Olysio's sales for the quarter are identified as $365 million. Olysio's actual sales were $354 million. The Fool regrets the error. Johnson and Johnson reported quarterly earnings on Tuesday, and one...
The S&P 500's 3 Biggest Biotech Losers of 2014
Keith Speights, The Motley Fool - Motley Fool - Wed Apr 16, 1:30PM CDT
What goes up must come down. The law of gravity applies to physics -- and the stock market. This has been readily apparent in 2014 with biotech stocks. After taking the world by storm over the previous two years, many stocks in the sector instead...
Midday Glance: Biotechnology companies
AP - Wed Apr 16, 12:30PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
Gilead Sciences Has Returned 12.6% Since SmarTrend Recommendation (GILD)
Comtex SmarTrend(R) - Wed Apr 16, 9:41AM CDT
SmarTrend identified a Downtrend for Gilead Sciences (NASDAQ:GILD) on March 13th, 2014 at $79.02. In approximately 1 month, Gilead Sciences has returned 12.56% as of today's recent price of $69.09.